Onchilles Pharma published a landmark study on the ELANE pathway and announced $25 million in financing to advance N17350, a cancer‑killing enzyme–based therapeutic, toward first‑in‑human studies. The company also named a leading clinical advisor to guide translational development. The capital injection will support IND‑enabling studies and early clinical work as Onchilles positions a potentially broad solid‑tumor approach derived from immune protease biology. Investors and collaborators will monitor safety, delivery strategy and biomarker plans as the program moves into the clinic.